With a revenue increase of 53.25% in the second quarter 2026, year on year to cumulative value of $129 million, Zevra Therapeutics Inc 's revenue per employee grew on a trailing twelve months basis to $ 2,112,377, this marks a new company high. Within the Healthcare sector Employees of 36 other companies have achieved higher revenue per employee. While revenue/employee total ranking has improved so far to 461, from total ranking in previous quarter at 648. Zevra Therapeutics Inc has 61 employees.
In a notable development within the biotechnology and pharmaceutical sector, all three leading proxy advisory firms, Institutional Shareholder Services (ISS), Glass Lewis, and Egan-Jones, have unanimously recommended that Zevra Therapeutics Inc. stockholders vote in favor of the company’s director nominees. This consensus comes in the wake of a rising chorus of challenges from activist investor proposals, underscoring the strength and potential of Zevra s management and strategic vision. Key Insights:1. Unanimous Endorsement from Proxy Firms: - ISS, Glass Lewis, and Egan-Jones concluded that dissident investor Frank Mangless has not provided a compelling case for change within the company. Their endorsement emphasizes confidence in Zevra s current leadership and strategic direction, reinforcing the stability of the company during a period fraught with challenges.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
